Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-301 (cosibelimab) in Advanced Cancers
NCT03212404Phase 1Active, not recruiting
- Sponsor
- Checkpoint Therapeutics, Inc.
- Start
- Sep 2017
- Primary completion
- Nov 2021
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Therapeutic Vaccines
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of cosibelimab-ipdl in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), endometrial cancer (EC) and 11 more, sponsored by Checkpoint Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Treatment-Emergent Adverse Events and 1 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
cosibelimab-ipdl
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)endometrial cancer (EC)cutaneous squamous cell carcinoma (cSCC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03212404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212404.